Rapamycin (Sirolimus) and Crohn's Disease: Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Rapamycin (Sirolimus) and Crohn's Disease: Latest Research 2026

This page summarizes the current state of scientific research on Rapamycin (Sirolimus) in the context of Crohn's Disease as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your gastroenterologist for personalized guidance.

Compound Overview

Rapamycin (Sirolimus) (mTOR Inhibitor / Macrolide) — FDA-approved as immunosuppressant and for certain cancers; longevity use is off-label

Mechanism of action: Allosteric inhibitor of mTORC1; activates autophagy; suppresses protein synthesis and cell proliferation

Current evidence level: Strong preclinical longevity data; established clinical use; PEARL trial studying longevity use

2026 Research Landscape

Direct research on Rapamycin (Sirolimus) specifically for Crohn's remains limited as of 2026, though the mechanistic connections continue to be explored in laboratory settings.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Rapamycin (Sirolimus) affects the biological pathways involved in Crohn's Disease progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Screening studies: Preclinical models are still being used to establish whether clinical investigation is warranted

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Rapamycin (Sirolimus)[tiab]) AND (Crohn's Disease[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Rapamycin (Sirolimus) keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Rapamycin (Sirolimus) + Crohn's research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in Crohn's patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Rapamycin (Sirolimus) for Crohn's?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Rapamycin (Sirolimus) Crohn's Disease' filtered to the last 2 years. The current evidence level is: Strong preclinical longevity data; established clinical use; PEARL trial studying longevity use.

Are there any 2025-2026 clinical trials for Rapamycin (Sirolimus) in Crohn's?

Check ClinicalTrials.gov with 'Rapamycin (Sirolimus)' as intervention and 'Crohn's Disease' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your gastroenterologist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Rapamycin (Sirolimus) in Crohn's changed recently?

The field evolves rapidly. The current evidence classification is: Strong preclinical longevity data; established clinical use; PEARL trial studying longevity use. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.